Following US pharmaceutical giant Pfizer’s failed attempt to acquire AstraZeneca, reports say Pfizer has inked a new joint venture deal to develop immunotherapy cancer drugs.

According to reports, Pfizer will team up with France-based Cellectis. The partnership involves Pfizer paying Cellectis $80 million upfront, as well as funding for ongoing research …read more

Source: Global Competition Law Blogs